Lifeboat Foundation

Hydrogen (like many of us) acts weird under pressure. Theory predicts that when crushed by the weight of more than a million times our atmosphere, this light, abundant, normally gaseous element first becomes a metal, and even more strangely, a superconductor—a material that conducts electricity with no resistance.

Scientists have been eager to understand and eventually harness superconducting hydrogen-rich compounds, called hydrides, for practical applications—from levitating trains to particle detectors. But studying the behavior of these and other materials under enormous, sustained pressures is anything but practical, and accurately measuring those behaviors ranges somewhere between a nightmare and impossible.

Like the calculator did for arithmetic, and ChatGPT has done for writing five-paragraph essays, Harvard researchers think they have a foundational tool for the thorny problem of how to measure and image the behavior of hydride superconductors at high pressure.

With six approved drugs, siRNA is now an established therapeutic modality poised for expansion.

Join this channel to get access to perks: https://www.youtube.com/channel/UC4AkVj-qnJxNtKuz3rkq16A/joinDon’t forget to check out my companion channels TnT Omn…

Do I want to do this now?

Summary: New research delves into how valence weighting bias—people’s tendency to prioritize negative or positive attitudes—plays a crucial role in procrastination. By studying individuals’ responses to tasks like tax filing and academic research participation, the researchers found a strong link between a negative-leaning attitude and the tendency to delay tasks.

Additionally, interventions that balanced participants’ valence weighting bias showed promise in reducing procrastination, suggesting that this psychological bias might be a key target for improving decision-making and task completion. This insight opens new avenues for addressing procrastination by adjusting how individuals weigh positive and negative signals when faced with decisions.

Aging reversed in dogs face_with_colon_three

Age-related decline in mobility and cognition are associated with cellular senescence and NAD+ depletion in dogs and people. A combination of a novel NAD+ precursor and senolytic, LY-D6/2 was examined in this randomized controlled trial. Seventy dogs were enrolled and allocated into placebo, low or full dose groups. Primary outcomes were change in cognitive impairment measured with the owner-reported Canine Cognitive Dysfunction Rating (CCDR) scale and change in activity measured with physical activity monitors. Fifty-nine dogs completed evaluations at the three-month primary endpoint, and 51 reached the six-month secondary endpoint. There was a significant difference in CCDR score across treatment groups from baseline to the primary endpoint (p=0.02) with the largest decrease in the full dose group. There were no significant differences between groups in changes in measured activity. However, the proportion of dogs that improved in frailty and owner-reported activity levels and happiness was higher in the full dose group than other groups. Adverse events occurred equally across groups. All groups showed improvement in cognition, frailty, and activity suggesting placebo effect and benefits of trial participation. We conclude that LY-D6/2 significantly improves owner-assessed cognitive function and may have broader effects on frailty, activity and happiness as reported by owners.

The authors have declared no competing interest.

Insomnia is a common sleep disorder. If you have it, you may have trouble falling asleep, staying asleep, or both. As a result, you may get too little sleep or have poor-quality sleep. You may not feel refreshed when you wake up.

What are the types of insomnia?

Insomnia can be acute (short-term) or chronic (ongoing). Acute insomnia is common. Common causes include stress at work, family pressures, or a traumatic event. It usually lasts for days or weeks.

The Artemis II mission is scheduled to put people back into lunar orbit in 2025, while the Artemis III will see humans return to the lunar surface no earlier than 2026, per Space. America’s manned mission to the moon is the marquee news, but the real news here is that the logo we most associate with NASA is called the “worm.” Quick! Put on some Beastie Boys, y’all, because NASA is once again doing the worm.

Artemis II Boosters Receive Iconic NASA “Worm”

The challenges of testing whether AI has rights.

Researchers’ findings have upended a long-held understanding of whether only opposites attract and like charges repel.